Acetylcholinesterase inhibitors reduce brain and blood interleukin-1β production

Yehuda Pollak, Adi Gilboa, Ofra Ben-Menachem, Tamir Ben-Hur, Hermona Soreq, Raz Yirmiya*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

97 Scopus citations


Overproduction of interleukin-1 within the brain is associated with Alzheimer's disease and other neurological conditions. We report that peripheral administration of the acetylcholinesterase inhibitors tacrine, rivastigmine, neostigmine, or EN101 (an antisense oligonucleotide directed at acetylcholinesterase messenger RNA) to mice significantly attenuated the production of interleukin-1β in the hippocampus and blood, concomitantly with the reduction in acetylcholinesterase activity. These findings demonstrate that cholinergic enhancement produces central and peripheral antiinflammatory effects and suggest a novel therapeutic mechanism for acetylcholinesterase inhibitors.

Original languageAmerican English
Pages (from-to)741-745
Number of pages5
JournalAnnals of Neurology
Issue number5
StatePublished - May 2005


Dive into the research topics of 'Acetylcholinesterase inhibitors reduce brain and blood interleukin-1β production'. Together they form a unique fingerprint.

Cite this